公开(公告)号：US20230202997A1

公开(公告)日：2023-06-29

申请号：US17928645

申请日：2021-06-02

Applicant: Sulfateq B.V.

Inventor： Hjalmar Roland BOUMA ,  Guido Krenning ,  Robert Henk HENNING ,  Adrianus Cornelis VAN DER GRAAF

IPC: C07D311/66 ,  A61P31/00 ,  C07D311/58 ,  C07D405/12

CPC classification number: C07D311/66 ,  A61P31/00 ,  C07D311/58 ,  C07D405/12

Abstract: The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment of sepsis and sepsis-induced organ dysfunction. Specifically, the present invention relates to chromanol compounds chosen from S-(6-hydroxy-2,5,7,8-tetramethylchroman-2yl)(piperazin-1-yl)methanone and S-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone, and pharmaceutically acceptable salts thereof.

公开(公告)号：US11730741B2

公开(公告)日：2023-08-22

申请号：US16640761

申请日：2018-08-23

Applicant: Sulfateq B.V.

Inventor： Robert Henk Henning ,  Gerrit Jan Willem Euverink ,  Guido Krenning ,  Adrianus Cornelis Van der Graaf

IPC: A61K31/5377 ,  A61K31/353 ,  A61K31/496 ,  A61K9/00

CPC classification number: A61K31/5377 ,  A61K31/353 ,  A61K31/496 ,  A61K9/0053

Abstract: The present invention relates to the (S) enantiomeric form of certain 6-chromanol derivatives for use as a medicament. Especially, the present invention relates to the (S) enantiomeric form of a 6-chromanol derivative for use as a medicament wherein said 6-chromanol derivative is chosen from the group consisting of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts or bases thereof and pharmaceutically acceptable salts thereof.

公开(公告)号：US20200206235A1

公开(公告)日：2020-07-02

申请号：US16640761

申请日：2018-08-23

Applicant: Sulfateq B.V.

Inventor： Robert Henk Henning ,  Gerrit Jan Willem Euverink ,  Guido Krenning ,  Adrianus Cornelis Van der Graaf

IPC: A61K31/5377 ,  A61K31/496 ,  A61K31/353

Abstract: The present invention relates to the (S) enantiomeric form of certain 6-chromanol derivatives for use as a medicament. Especially, the present invention relates to the (S) enantiomeric form of a 6-chromanol derivative for use as a medicament wherein said 6-chromanol derivative is chosen from the group consisting of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts or bases thereof and pharmaceutically acceptable salts thereof.

公开(公告)号：US12156862B2

公开(公告)日：2024-12-03

申请号：US16640785

申请日：2018-08-23

Applicant: Sulfateq B.V.

Inventor： Robert Henk Henning ,  Gerrit Jan Willem Euverink ,  Guido Krenning ,  Adrianus Cornelis Van der Graaf

IPC: A61K31/353

Abstract: The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions. A preferred 6-chromanol derivative is (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.

公开(公告)号：US20210128523A1

公开(公告)日：2021-05-06

申请号：US16640785

申请日：2018-08-23

Applicant: Sulfateq B.V.

Inventor： Robert Henk Henning ,  Gerrit Jan Willem Euverink ,  Guido Krenning ,  Adrianus Cornelis Van der Graaf

IPC: A61K31/353

Abstract: The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions. A preferred 6-chromanol derivative is (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.